ATLAS-1: Advanced Trial for Longitudinal Assessment in Salma 1

This study will evaluate the feasibility and clinical utility of developing predictive models of treatment response for patients with depressed mood using multimodal clinical data collected in real-world clinical settings. The study will examine outcomes among patients treated with interventions including esketamine, conventional transcranial magnetic stimulation (TMS), or Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT). Retrospective clinical and research data from existing databases may also be incorporated, when available and authorized, to support model development and validation. The goal is to assess whether integrated clinical datasets can be used to support the development of predictive tools that may inform personalized treatment selection in depression.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Depressed Mood Behavior Behavioral Symptoms Consciousness Disorders Depression Depressive Disorder Depressive Disorder, Major Depressive Disorder, Treatment-Resistant Mental Disorders Mood Disorders Nervous System Diseases Neurobehavioral Manifestations Neurocognitive Disorders Neurologic Manifestations Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Salma Health, La Jolla, California, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adults (≥18 years) of any gender identity presenting for care with a depressed mood.
Prescribed treatment with esketamine, conventional TMS, or SAINT as part of standard clinical care.
Able to provide informed consent and comply with all study requirements.

Exclusion criteria

Any condition deemed by the investigator to preclude safe participation in study assessments.

Treatment and study plan

Primary outcomes

Patient Health Questionnaire 9-item (PHQ-9)

Time frame: Pre-treatment, Post-treatment, 2 weeks posttreatment, and Monthly post-treatment for 12 months

The Patient Health Questionnaire (PHQ-9) is a 9-item multipurpose self-report instrument for screening, diagnosing, monitoring and measuring the severity of depression.

Sponsors and collaborators

Lead sponsor

Salma Health, Inc.

Other

Collaborators

Center for Neurohealth, Inc

Registry information

Acronym: ATLAS-1

Important dates

Study start: 2026
Primary completion: 2036
Study completion: 2037
First posted: Apr 14, 2026
Registry last updated: Apr 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting